{"entity":{"id":"accent-therapeutics","kind":"company","name":"Accent Therapeutics","aka":[],"tldr":"Accent Therapeutics makes tablets aimed at cancers whose cells carry the wrong number of chromosomes, a weakness that healthy cells do not share. Its lead medicine is being tested in ovarian and squamous lung cancer.","summary":"Accent Therapeutics, based in Lexington, Massachusetts, develops oral small molecules against dependencies created by genomic and chromosomal instability. Its lead programme ATX-295 is an inhibitor of the mitotic kinesin KIF18A, which the company describes as selectively essential in tumours with high chromosomal instability; it is in a phase 1/2 trial (NCT06799065) in advanced or metastatic solid tumours including high-grade serous ovarian cancer and squamous non-small cell lung cancer, and the company states it keeps full worldwide rights to the programme. A second clinical programme, ATX-559, an oral inhibitor of the RNA helicase DHX9, entered a first-in-human trial in molecularly defined cancers (NCT06625515), which the registry lists as terminated. The company reported FDA Fast Track designation for both ATX-295 and ATX-559 in April 2025, and in October 2025 announced that Boehringer Ingelheim had obtained a preclinical oncology programme from it. Its first registered cancer trial, NCT06625515, was posted on ClinicalTrials.gov in October 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://accenttx.com/"},{"label":"Approach and pipeline","url":"https://accenttx.com/approach-pipeline/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of ATX-295 (NCT06799065)","url":"https://clinicaltrials.gov/study/NCT06799065"},{"label":"ClinicalTrials.gov: first-in-human trial of ATX-559 (NCT06625515)","url":"https://clinicaltrials.gov/study/NCT06625515"}],"tags":[],"related":[],"cancers":["high-grade-serous-ovarian-cancer","platinum-resistant-ovarian-cancer","lung-squamous-cell-carcinoma"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches"],"targets":["dhx9"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website, read on 29 October 2026.","No financing round is recorded because no company release stating an amount was read.","Trial status for NCT06625515 (terminated) and NCT06799065 (recruiting) comes from the ClinicalTrials.gov records read on 29 October 2026; the reason for termination was not read."],"hq":"Lexington, MA","country":"US","companyType":"biotech","website":"https://accenttx.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/accent-therapeutics/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/"}]}}